Brandy is back with us, MSNBC senior reporter. And if I go back to this winter, Brandy, there was an airplane ride that I had from West Palm Beach covering Donald Trump down in Marago. And I was coming back here to New York and Dan Weldon's name was popped up.It was like 9:00 p. m. at night.He was being tapped to be the CDC director. Started doing some research. He's in that Rolling Stone retracted article that RFK Jr.. wrote and essentially Dan Weldon's name was relevant because he was the former congressm ...

Ironically, the reason the system is buckling now may be because they gave us so many childhood vaccines.Rothmus 🏴 (@Rothmus):https://t.co/qb8NQ5EhL1 ...

There were antivaccine lawyers in the room that you could kind of overhear talking about something called the vaccine um uh injury compensation program, which is this program that it's like vaccine court. It's how people um get claims for the very rare vaccine injuries that do happen. Those that court has been sort of flooded with people who've been turned away and their cases dismissed, many of whom testified today as a witness.Um but what was it like in there. It was super sad. Yeah, it was a bunch of peo ...

Opioid Crisis & Regulatory Reform - FDA 承认在阿片类药物监管方面存在失败，并对由此造成的阿片类药物滥用危机表示担忧 [1] - FDA 计划审查 OxyContin 等药物的标签，确保其准确性并与科学依据相符 [2] - FDA 致力于移除咨询委员会中所有可能的行业成员，以维护科学流程的公正性 [3] - FDA 将加强对已批准药物的上市后监测，利用大数据识别潜在的安全信号 [3][4] - FDA 将取消阻止安全流行病学研究的权限，确保安全团队能够自由工作，避免利益冲突 [5] Drug Approval & Transparency - FDA 正在进行全国范围的意见征集，听取 CEO 们对改进 FDA 的想法 [13] - FDA 致力于提高透明度，公开决策信函，使药品开发商能够了解药品未被批准的原因 [14][17] - FDA 正在利用 AI 技术来组织和分析大量的申请文件，以实现现代化 [18] - FDA 推出了一项试点计划，对于符合美国国家优先事项的药物，提供优先审查凭证，将决策时间缩短至 1-2 个月 [20] - FDA 员工数量自 2007 年以来翻了一番，存在大量冗余，需要进行整合 [21] Investment & Deregulation - FDA 采取放松监管的态度，旨在加快审批流程，同时不降低安全标准 [23] - FDA 将与行业保持沟通，确定哪些产品符合国家优先事项，例如满足未满足的公共卫生需求、实现国内生产以及提高药品的可负担性 [24] - FDA 计划对承诺在 OECD 国家和美国之间实现药品价格均等化的公司发放国家优先审查凭证，以激励市场中的良好行为 [25]

100 days on the job, FDA Commissioner Dr. Marty Makary discusses HHS Secretary Robert F. Kennedy Jr.’s complicated stance on vaccines and the future of public trust in American health care agencies. The White House is mounting pressure on Federal Reserve Chair Jerome Powell; Office of Management and Budget Director Russell Vought explains that he’s pushing the central bank on its monetary policy and, more recently, on its building renovations. Plus, President Trump is threatening a 35% tariff on Canada, and ...

The American Academy of Pediatrics is suing HHS Secretary RFK Jr. . saying, quote, "We believe the children deserve better." The lawsuit alleges changes to COVID vaccine recommendations without a scientific reason. And Kennedy's firing of vaccine advisors, replacing them with multiple vaccine skeptics, are illegal and are outside established scientific practice.Joining us now, the president of the American Academy of Pediatrics, Dr. . Susan Cresley. Uh, doctor, thank you so much for joining us.Um, please ex ...

Moderna says its experimental flu shot met its goal in a late-stage trial, clearing the path for its broader strategy of selling combination vaccines https://t.co/93QBuninAV ...

Public Health & Vaccine Advisory Committee Concerns - The Advisory Committee on Immunization Practices (ACIP) fine-tunes vaccine guidelines annually, impacting US immunization programs and global models [1][2] - The health secretary replaced 17 ACIP members with seven new appointees, raising concerns about qualifications and potential anti-vaccine bias [2] - Appointees include individuals who previously urged reopening schools/businesses early in the pandemic and those associated with vaccine misinformation sources [3][4] - Senator Bill Cassidy called for delaying the ACIP meeting due to appointees' lack of relevant expertise and potential bias against mRNA vaccines [6] - An infectious disease epidemiologist described the ACIP panel as "platforming misinformation and manipulating data" [9] Vaccine Misinformation & Public Confusion - The appointment of vaccine skeptics to the federal vaccine committee is seen as a setback to public health [11] - Concerns exist that conflicting information from health organizations like the American Academy of Pediatrics and the CDC may arise due to the new appointments [17] - Global vaccination rates have dropped, leading to a 20% increase in measles diagnoses worldwide since 2022 [18][19] - Misinformation, such as claims about thimerosal causing autism, continues to be promoted despite scientific evidence to the contrary [7][8][20] - The twisting of scientific information, like ethyl mercury versus methyl mercury, contributes to public confusion and distrust in vaccines [23] Potential Solutions & Future Outlook - Medical experts are forming an alternative vaccine advisory panel called the Vaccine Integrity Project to provide accurate information [17] - There is hope that the potential CDC director appointee, Susan Monarees, will uphold scientific evidence and confront the vaccine advisory committee if necessary [26][27] - Neutralizing the misinformation spread by vaccine skeptics is crucial to maintaining public health [15]

Core Insights - GSK stock has increased by 21.5% over the past six months, driven by strong performance in the Specialty Medicines unit, regulatory successes, and a positive long-term outlook despite challenges in the Vaccines unit and economic pressures [2][22]. Specialty Medicines Unit Performance - The Specialty Medicines unit has shown significant sales growth, with a 19% increase in 2024 and a 17% rise in Q1 2025, primarily due to successful launches in Oncology and long-acting HIV medicines [3][4]. - Key products driving growth include Nucala, Dovato, Cabenuva, Apretude, Jemperli, and Ojjaara, with expectations for low double-digit sales growth in 2025 despite the Inflation Reduction Act's impact [4][9]. - Specialty Medicines currently accounts for approximately 40% of GSK's sales and is projected to exceed 50% by 2031 [4]. Promising Pipeline Developments - GSK is increasing R&D investments in long-acting and specialty medicines across various therapeutic areas, including Respiratory, Immunology & Inflammation, Oncology, and HIV [5]. - Recent approvals include the pentavalent MenABCWY vaccine and Blujepa for UTI treatment, with Nucala receiving approval for COPD in May 2025 [5][6]. - GSK anticipates launching five new products in 2025, including Blenrep and depemokimab, with several already approved in the U.S. [7]. Vaccine Sales Challenges - Vaccine sales declined by 6% in Q1 2025, primarily due to lower demand for the RSV vaccine Arexvy and shingles vaccine Shingrix [8][10]. - Shingrix sales fell by 21% in Q1 2025, and Arexvy's global sales dropped by 57%, attributed to revised vaccination recommendations and challenges in reaching consumers [10][11]. - The company expects a low single-digit percentage decline in Vaccine sales for 2025 due to macroeconomic challenges and potential policy changes [12]. Stock Performance and Valuation - GSK stock has outperformed the industry and S&P 500, rising 20.1% year-to-date compared to a 4.0% industry increase [13]. - The stock trades at a forward P/E of 8.63, below the industry average of 15.63, indicating an attractive valuation relative to peers [17]. - Earnings estimates for 2025 have increased from $4.26 to $4.42 per share, reflecting analysts' positive outlook for future growth [20]. Future Growth Expectations - GSK anticipates over 7% sales growth and more than 11% core operating profit growth on a CAGR basis from 2021 to 2026, driven by Specialty Medicines and improvements in General Medicines [23]. - The company has resolved most Zantac litigations, alleviating a significant overhang on the stock [25].

Welcome to the beat everyone. We're monitoring live pictures from Los Angeles as we come on the air right now. People are continuing these protests after what has widely been reported as the Trump administration's escalation. 700 Marines now deployed by the administration arriving today. You can see some of the indications of this type of military presence on American streets. This is a rare effort to deploy US troops inside the US for what would seem like policing purposes, although the details are in deba ...